Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 19 06 2024
accepted: 02 09 2024
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: aheadofprint

Résumé

In prion diseases (PrDs), aggregates of misfolded prion protein (PrPSc) accumulate not only in the brain but also in extraneural organs. This raises the question whether prion-specific pathologies arise also extraneurally. Here we sequenced mRNA transcripts in skeletal muscle, spleen and blood of prion-inoculated mice at eight timepoints during disease progression. We detected gene-expression changes in all three organs, with skeletal muscle showing the most consistent alterations. The glutamate-ammonia ligase (GLUL) gene exhibited uniform upregulation in skeletal muscles of mice infected with three distinct scrapie prion strains (RML, ME7, and 22L) and in victims of human sporadic Creutzfeldt-Jakob disease. GLUL dysregulation was accompanied by changes in glutamate/glutamine metabolism, leading to reduced glutamate levels in skeletal muscle. None of these changes were observed in skeletal muscle of humans with amyotrophic lateral sclerosis, Alzheimer's disease, or dementia with Lewy bodies, suggesting that they are specific to prion diseases. These findings reveal an unexpected metabolic dimension of prion infections and point to a potential role for GLUL dysregulation in the glutamate/glutamine metabolism in prion-affected skeletal muscle.

Identifiants

pubmed: 39259763
doi: 10.1371/journal.ppat.1012552
pii: PPATHOGENS-D-24-01272
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1012552

Informations de copyright

Copyright: © 2024 Caredio et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Davide Caredio (D)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Maruša Koderman (M)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Karl J Frontzek (KJ)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.

Silvia Sorce (S)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Mario Nuvolone (M)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Juliane Bremer (J)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Giovanni Mariutti (G)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Petra Schwarz (P)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Lidia Madrigal (L)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Marija Mitrovic (M)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Stefano Sellitto (S)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Nathalie Streichenberger (N)

Médecin praticien hospitalier en Neuropathologie chez Hospices Civils de Lyon, France.

Claudia Scheckel (C)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Adriano Aguzzi (A)

Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Classifications MeSH